Aurobindo Reprimanded By SEBI Over US FDA Warning Disclosure

‘Very Limited And Restricted Information’ Revealed By Indian Firm Deemed ‘Insufficient’

 
• By David Wallace
  
Securities and Exchange Board of India (SEBI) Logo
The Securities and Exchange Board of India says Aurobindo’s disclosures were not sufficient • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Manufacturing

More from Business